Immune to Cancer: The CRI Blog
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
-
FDA Approves First-In-Class CAR T Cell Immunotherapy for Leukemia
Children and young adults with relapsed/refractory acute lymphoblastic leukemia (ALL) can now receive the CD19-targeting CAR T…
-
Highlights of the 2nd Annual Rational Combinations 360° Conference
Biomarkers will be crucial to taking advantage of combination immunotherapy’s full potential
-
AACR17 Update: CAR T Cells, Regulatory T Cells, and the Future of Immunotherapy
Day two addressed several strategies to improve immunotherapy’s precision and effectiveness
-
Cancer Immunotherapy Goes Viral
A deadly virus that has killed more than 25 million people over the past 32 years has…